Answers are grounded in this paper and cite their sources.
Purpose: To compare the baseline visual and anatomical parameters between the woman andmen with diabetic macular edema (DME) who underwent intravitreal ranibizumab treatment.Materials and Methods: This was a retrospective case-control study. Treatment naïve DMEpatients who were newly diagnosed and completed a follow time of 12 months in our clinicwere included. All the patients were prescribed to receive a loading dose of three consecutive monthly injections. Then the patients were followed monthly, and treated on a pro-re-natatreatment regimen. Primary outcome measures of this study was the baseline best correctedvisual acuity (BCVA) and central retinal thickness (CRT) in the female and male patients atthe baseline. Secondary outcome measures were the change in BCVA and CRT during the 12months follow-up period.Results: Sixty-three eyes of 44 women, and 110 eyes of 76 men were included in the study.The mean baseline BCVA of the women was 0.72±0.44 (range 0.1-2.0) LogMAR, and themen was 0.49±0.31 (range 0.0-2.0) which was statistically significant between the two groups(p<0.0001). The mean baseline CRT of the women was 484±117 microns (range 312-759),and the men was 467±100 microns (range 320-704) (p=0.3). The mean visit number in womenand men groups were 4.6±0.9 and 4.5±1.0, respectively (p=0.5). The mean injection number inwomen and men groups were 4.1±1.6 and 3.8±1.4, respectively (p=0.2).Conclusion: Our results revealed that there may be a significant difference in baseline BCVAbetween women and men with DME at the first admittance. Perhaps we should be more sensitive in periodic ophthalmology consultations of women with DME and warn the general healthcare practitioners, internal medicine specialists and endocrinologists in this regard.
No takes yet. Share an insight, caveat, or question.
Özkaya et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: